Drugmaker Ipsen Picks Lazard for Review of Consumer Health Unit

Ref: Bloomberg
  • Ipsen is working with Lazard on a strategic review of its consumer health unit, a spokesperson for Ipsen said, Bloomberg reported. 

  • According to people with knowledge of the matter, the business could be valued at as much as $500 million in a potential sale.

  • The drugmaker’s consumer health unit is likely to draw interest from both strategic and financial investors, the people said. Ipsen announced a strategic review of the unit in December. 

  • The company’s consumer health unit generated sales of about 211 million euros last year, according to its website.